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Public health and regulatory efforts in the
United States have achieved great successes
over the last 40 years regarding environmen-
tal lead exposure. Chronological trend data
from the National Health and Nutrition
Examination Surveys have documented a
decline in average adult blood lead levels from
approximately 15 µg/dL in the 1970s to the
current 1–2 µg/dL (Annest et al. 1983;
Muntner et al. 2005; Pirkle et al. 1998).
Similar changes have occurred in children in
the context of recommendations by the U.S.
Centers for Disease Control and Prevention
CDC) for a progressive decline in the level of
concern of lead in a child’s blood that should
trigger other specific actions (from 40 to
30 µg/dL in 1975, 30 to 25 µg/dL in 1985,
and 25 to 10 µg/dL in 1991). This trend was
driven by a steady accumulation of research
that demonstrates adverse effects in children
at progressively lower levels of exposure and
reﬂects the success of a number of regulatory
actions that removed lead from gasoline and
many other consumer products such as paints
and solder used for plumbing and food cans. 
In contrast, despite a growing body of
research that demonstrates adverse effects in
adults at progressively lower levels of exposure,
the lead standards of the U.S. Occupational
Safety and Health Administration (OSHA),
promulgated in ﬁnal form for general industry
(29 CFR 1910.1025; OSHA 2006a) in 1978
and for construction (29 CFR 1926.62;
OSHA 2006b) in 1993 have not changed in
their allowance that workers can attain blood
lead levels up to 40 µg/dL for their working
lifetimes. OSHA, relying on studies at that
time, developed these standards when most
workers started employment in lead-exposed
jobs with average blood lead levels in the 
10- to 15-µg/dL range because of high envi-
ronmental exposures. As such, the research
that formed the basis of the health protection
goals in the standards was primarily from the
1960s and 1970s and earlier. This lack of
change has no doubt contributed to a trend in
occupational lead exposure that has not
declined as steeply as environmental lead
exposure. In 2002, a total of 10,658 adults
with blood lead levels of ≥ 25 µg/dL were
reported to the CDC by 35 states (CDC
2004). Of these, 1,854 had levels of
≥ 40 µg/dL. These numbers are likely to
underestimate the true magnitude of the
problem because many workers who should
be in employer-sponsored surveillance pro-
grams to follow their blood lead concentra-
tions are not well monitored (Nelson and
Kaufman 1998; Papanek et al. 1992; Rudolph
et al. 1990).
The recognition of the inadequacy of the
OSHA lead standards is not new (Landrigan
et al. 1990; Silbergeld et al. 1991). However,
the quality of the evidence demonstrating
that lead exposure at levels below the
OSHA standard is associated with signiﬁcant
adverse effects has dramatically improved.
Epidemiologic methods in general and as
applied to research on the health effects of lead
have evolved considerably during this time,
with more rigorous attention to study design,
subject selection, causal pathways, lead dose,
lead biomarkers, and genetic susceptibility fac-
tors, particularly regarding such issues as tim-
ing and accumulation of dose and the
development of acute and chronic health
effects. Acute health effects due to recent dose
are thought more likely to be reversible in
nature, whereas chronic health effects due to
cumulative dose are thought more likely to be
irreversible in nature. It is thus critical to




This mini-monograph is meant to serve
several purposes. First, it provides recommen-
dations to the medical and public health
communities in the medical management of
adults with lead exposure. Second, it is a dis-
cussion of the state-of-the-art thinking on
epidemiologic studies of the health effects of
lead in adults, particularly regarding the use
and interpretation of lead biomarkers, study
population and design issues, and complex
causal pathways involving how lead affects
human health. Third, the mini-monograph
includes two systematic reviews (Navas-Acien
et al. 2007; Shih et al. 2007) of epidemiologic
evidence regarding two of the most important
health outcomes associated with lead, speciﬁ-
cally, the effects on the cardiovascular and
central nervous systems. 
Currently, no other similar compilations
have summarized recent scientiﬁc ﬁndings and
their relevance to clinical and public health
practice regarding lead-exposed adults.
Furthermore, although many authors have
increasingly recognized the importance of
recent and cumulative lead dose as predictors
of adverse health effects, especially for lead, no
documents have summarized these issues and
their relevance to protection of lead-exposed
adults, or made recommendations for protec-
tion that use limits on both recent dose and
cumulative dose. Finally, it is a call to action.
The OSHA lead standards provide inadequate
protection to lead workers; the existing evi-
dence is compelling that we are subjecting
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We have assembled this mini-monograph on adult lead exposure to provide guidance to clinicians
and public health professionals, to summarize recent thinking on lead biomarkers and their rele-
vance to epidemiologic research, and to review two key lead-related outcomes, namely, cardiovascu-
lar and cognitive. The lead standards of the U.S. Occupational Safety and Health Administration
are woefully out of date given the growing evidence of the health effects of lead at levels of exposure
previously thought to be safe, particularly newly recognized persistent or progressive effects of
cumulative dose. The growing body of scientific evidence suggests that occupational standards
should limit recent dose to prevent the acute effects of lead and separately limit cumulative dose to
prevent the chronic effects of lead. We hope this mini-monograph will motivate renewed discussion
of ways to protect lead-exposed adults in the United States and around the world. Key words:
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both acute and chronic health effects.
We have assembled ﬁve articles, including
the present article, into this mini-monograph
on adult lead exposure (Hu et al. 2007;
Kosnett et al. 2007; Navas-Acien et al. 2007;
Shih et al. 2007). As described below, the
mini-monograph was motivated largely by the
work of a national expert panel on adult lead
exposure that spent over 2 years discussing
these issues. In this first article, we describe
the history and limitations of the OSHA lead
standard, the process of the expert national
panel, the purpose of the other articles in the
mini-monograph, and provide some personal
recommendations on what is required to pro-
tect workers from the health effects of lead.
Process for Development of
the Guidelines
The ﬁrst impetus for the articles assembled in
the mini-monograph was from the Adult
Blood Lead Epidemiology and Surveillance
(ABLES) Program, a National Institute for
Occupational Safety and Health (NIOSH)
endeavor currently operating in 38 states. In
2000, ABLES formed an ad hoc Committee
for the Development of Adult Blood Lead
Level Medical Management Guidelines and a
draft document was produced (unpublished).
The Association for Occupational and
Environmental Clinics (AOEC) agreed to
sponsor the next steps in the review and revi-
sion of the draft document, and obtained fed-
eral funding in support of this activity. AOEC
next assembled a panel of 13 experts with
training and experience in the areas of lead
toxicology, epidemiology, occupational medi-
cine, occupational health nursing, industrial
hygiene, and public health policy and practice,
from academic institutions, government, labor
organizations, and industry to review the doc-
ument. Panel members included (in alphabeti-
cal order) Rose Goldman, Dana Headapohl,
Karen Hipkins, Howard Hu, Michael
Kosnett, Barbara Materna, Pamela Reich,
Stephen Rothenberg, Brian Schwartz, Eugene
Shippen, Richard Wedeen (Panel Chair),
Laura Welch, and Alan Woolf. Kathy
Kirkland (Executive Director of the AOEC),
coordinated the activities of the panel.
The panel met in March 2003 in
Washington, DC, and then held a series of
conference calls through 2005 to make revi-
sions to the document. At the onset, the panel
chose to focus on health-based recommenda-
tions and not to explicitly consider feasibility of
implementing these guidelines. The panel also
generally decided not to explicitly consider
socioeconomic considerations for lead workers,
for example, if a cumulative lead dose limit
required workers currently in the lead-using
industries to discontinue all further work in
lead and thus had to leave their jobs. Measures
designed to protect health may incur unaccept-
able costs to individual workers and industry,
but the considerations of panel members and
authors of the articles in the mini-monograph
were solely motivated by scientific evidence
regarding health. Conclusions stated in all arti-
cles in the mini-monograph are not intended
to be enforceable standards, which by law must
reﬂect feasibility and experience gained under
OSHA and other health and safety laws. The
third article (Kosnett et al. 2007) in the mini-
monograph was prepared by a subgroup of
panel members (8 of 13 members) who were
interested in and willing to continue to work
on these issues after the work of the panel
ended. The article is not a systematic review
but rather panel members relied on selected,
inﬂuential published articles within the extant
literature as well as experience and expert opin-
ion to come to consensus in reaching the arti-
cle’s recommendations. However, it represents
only the opinions of its authors.
Overall, there was a remarkable degree of
consensus among panel members. The two
industry representatives on the panel voiced a
number of concerns during the process, but
other panel members generally agreed on all
but a few points. Although the panel made
considerable progress in reaching consensus, a
number of challenges to its process must be
acknowledged. Funding was available only for
one face-to-face meeting. This meeting high-
lighted many difﬁcult issues that needed con-
tinued analysis and discussion, but all further
discussion was only available by conference
call. In contrast to typical Institute of
Medicine (IOM) committees charged with
reviewing scientiﬁc evidence and making rec-
ommendations for public health or clinical
medicine (National Academy of Sciences
2006), our committee had more limited
resources and lacked an agreed upon, stan-
dardized approach to review of the evidence
and presentation of its analysis and summary,
as is used by IOM committees. Despite these
limitations, the majority of panel members
supported the final document in the
mini-monograph, which provides clear rec-
ommendations on a number of management
approaches for lead-exposed adults that we
believe will be useful to public health and
clinical practitioners.
Brief Review of Requirements
of the OSHA Lead Standards
A review of the OSHA lead standards and
their preambles allows several conclusions.
First, the standards emphasize prevention of
acute symptoms in several organ systems and
prioritize other measurable health effects in a
way that is likely to be considered differently
today. Most health effects that are considered
are of relatively short latency and are more
likely to occur after high-level, short-term
exposures. For example, there is extensive dis-
cussion of the hematopoietic system in which
measurable health effects occur with short
latency after moderate to high lead exposures
and very little consideration of long-latency,
chronic health effects. Such chronic health
outcomes as cognitive dysfunction, hyperten-
sion risk, and renal dysfunction after long-
term, low-level exposures were not considered
in any substantive detail. So, while the OSHA
standards mainly focused on prevention of
symptoms, hematopoietic outcomes, and renal
dysfunction associated with high-level expo-
sures, the highest priority concerns of today
would be cognitive decline, hypertension and
other cardiovascular outcomes, long-latency
renal disease, and reproductive outcomes. 
Second, the standards considered the level
of lead in whole blood to be the key lead bio-
marker and, although not explicitly discussed,
blood lead was generally used only as a meas-
ure of relatively recent dose. There was no
consideration of cumulative dose or long-term
lower-level exposures despite the fact that
many health outcomes associated with envi-
ronmental exposures are due to cumulative
dose (e.g., environmental tobacco smoke and
lung cancer) and the fact that lead was known
to accumulate in bone and thus has long resi-
dence times in the body. Health physicists
were developing and validating X-ray ﬂuores-
cence (XRF) systems for measurement of lead
in bone at that time, but certainly by the late
1980s or early 1990s, there was extensive
experience with measurement of lead in bone
by cadmium-109–induced K-shell XRF, if not
widespread availability. Third, there was no
consideration about whether health effects
could progress after cessation of occupational
exposure. Finally, there was little consideration
of susceptible subgroups such as older individ-
uals or those with certain genetic polymor-
phisms. In fairness, little was known about
genetic susceptibility to lead poisoning in the
1970s, but a large number of studies have
been published on the topic since that time.
Any new recommendations for occupational
lead exposure standards should recognize that
there are susceptible subgroups and limits
should protect the most susceptible workers. 
Under the OSHA standards, medical sur-
veillance is an essential part of an employer’s
lead safety program and includes biological
monitoring with periodic blood lead testing,
medical evaluation, and treatment if needed,
and intervention to prevent or control expo-
sure levels. Employers must offer medical sur-
veillance to workers if airborne lead exposure
is 30 µg/m3 (8-hr time-weighted average) or
higher for > 30 days/year. Although slight dif-
ferences exist in the two OSHA lead stan-
dards, OSHA requires that workers in general
industry be removed from further lead expo-
sure if a single blood lead level is ≥ 60 µg/dL,
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average ≥ 50 µg/dL, until levels decline to
< 40 µg/dL. An important implication of
these limits is that, because OSHA accepts a
blood lead level of 40 µg/dL for a working
lifetime (40 years), a cumulative blood lead
index of 1,600 µg-years/dL (calculated as the
average blood lead level multiplied by the
years over which it is averaged, or, more accu-
rately as the area under the curve of blood
lead versus time) is an acceptable cumulative
dose. As discussed in greater detail in the sec-
ond article (Hu et al. 2007) in the mini-
monograph, this cumulative blood lead index
would result in a bone lead level (in the tibia)
at the end of employment of 80–160 µg
lead/g bone mineral. This mini-monograph
provides extensive evidence that this cumula-
tive dose is associated with substantial adverse
health risks.
If new OSHA standards are developed
and promulgated, there will arise a number of
complex and challenging issues. For example,
because of the signiﬁcant reduction of lead in
the general environment, new workers will
enter lead jobs with very low blood lead lev-
els, whereas others who have worked with
lead or who are older will have much higher
blood lead levels and body burdens. This may
motivate employers to hire younger workers
and terminate older workers. This mini-
monograph does not address these complexi-
ties and leaves consideration of these issues to
future efforts.
New Evidence on the Health
Effects of Lead
The growth in knowledge about the health
effects of lead has been dramatic since the pro-
mulgation of the OSHA lead standards. For
example, in 1995, Balbus-Kornfeld et al.
(1995) reported there was no evidence for or
against the hypothesis that cumulative lead
dose caused cognitive dysfunction or decline,
because no epidemiologic studies had esti-
mated cumulative dose and the four existing
prospective studies were small, with relatively
low follow-up rates, and of relatively short
duration. As discussed in the second article
(Hu et al. 2007) in the mini-monograph, lon-
gitudinal studies provide critical evidence
because confounding is less likely to invalidate
inferences and such studies allow differentia-
tion of reversible, persistent, and progressive
health effects, which also requires that occupa-
tional exposures have ended. Since that time,
at least 20 papers have been published (or are
in press) that document studies measuring
cognitive function, blood lead, and bone lead,
thereby allowing more careful consideration of
recent and cumulative dose than in earlier
studies. This dramatic growth in scientiﬁc evi-
dence has not been confined to cognitive
function; similar, if not greater, growth has
occurred regarding other important health
effects of lead exposure such as hypertension
and other cardiovascular outcomes (Lustberg
and Silbergeld 2002) and renal disease
(Weaver et al. 2005). These new studies allow
much better evaluation of such key issues as
recent, intermediate-term, and cumulative
dose; acute and chronic health effects; and
reversibility, persistence, or progression of
health effects.
Recommendations for a New
OSHA Standard
In our opinion, which does not necessarily
represent the view of the expert panel, we
believe that lead poisoning must be thought
about as a chronic disease. Once a signiﬁcant
lead body burden has accumulated, the health
effects are likely to be progressive and, to a
large degree, irreversible. Like diabetes and
other chronic diseases, these health conditions
can be managed, but some health conse-
quences may not be preventable after a cumu-
lative dose threshold is exceeded. We must
prevent cumulative dose, not just follow
blood lead levels. We must focus on preven-
tion of long-term, progressive health effects,
such as cognitive decline, and the increased
risk of cardiovascular and circulatory mortal-
ity. We must also prevent the shorter latency
health effects of recent dose, as reflected in
blood lead levels, such as elevations in blood
pressure and the cognitive dysfunction pre-
sent at only moderate blood lead levels. We
must acknowledge that there are likely to be
susceptible subgroups, as suggested by recent
studies demonstrating worse lead-associated
outcomes in persons with certain polymor-
phisms in the apolipoprotein E (Stewart et al.
2001), vitamin D receptor (Lee et al. 2001a,
2001b; Schwartz et al. 2000a, 2000b),
Na+,K+-ATPase (Glenn et al. 2001), and
δ-aminolevulinic acid genes (Bergdahl et al.
1997; Schwartz et al. 2000a, 1997; Wetmur
1994; Wetmur et al. 1991; Wu et al. 2003),
protein kinase C phenotypes (Hwang et al.
2002), and persons with other common
chronic diseases such as type II diabetes
(Tsaih et al. 2004), and promulgate lead stan-
dards that prevent adverse health outcomes in
these most susceptible subgroups.
We recommend that OSHA modify the
lead standards to prevent both the acute
health effects of recent dose and the chronic
health effects of cumulative dose. It should be
noted that the members of the panel consid-
ered the use of tibia lead levels and cumula-
tive blood lead index in detail, but concluded
they could not recommend routine clinical
use of the former because of limited avail-
ability and the on-going but incomplete
development of standardized protocols for
intercalibration—the latter because of
concerns about logistics and practicality.
However, the panel recognized that the main
advances in epidemiologic research on the
health effects of lead in the past two decades
have been recognition of the importance of
cumulative dose and that a single or few
blood lead levels do not estimate cumulative
dose. Accumulation of dose in this context is
a critically important concept that has not
been generally considered in occupational
safety and health regulations to date and is
the motivation for many of the recommenda-
tions in this mini-monograph. 
We would favor limits that keep blood
lead levels < 20 µg/dL to prevent the acute
effects of recent dose. For the prevention of
the chronic health effects of cumulative dose,
the available evidence suggests that tibia lead
levels should not be allowed to exceed 15 µg
lead/g bone mineral; this could also be
achieved by maintaining the cumulative
blood lead index below approximately
200–400 µg-years/dL (equivalent to an aver-
age blood lead level of 20 µg/dL for
10–20 years or of 10 µg/dL for 20–40 years).
Unfortunately, other scientists and public
health professionals made similar recommen-
dations more than 15 years ago (Landrigan
et al. 1990; Silbergeld et al. 1991), and little
has resulted. We hope this mini-monograph
will have a larger impact on policy.
These recommendations require more
stringent exposure limits than currently exist
in the OSHA standards and a tighter link
between exposure and dose in surveillance
programs. The OSHA permissible exposure
limit of 50 µg/m3 was based on industry
claims of feasibility for engineering and venti-
lation controls, but current technologies are
better than those that were available in the
1970s. However, the lower limits may require
greater reliance on respirators, which will have
implications for both workers and employers.
Organization of the
Mini-Monograph
The mini-monograph consists of four other
articles: 
The article by Hu et al. (2007) is a review
of issues surrounding epidemiologic methods
of particular relevance to studies of the health
effects of lead, lead exposure and dose, and lead
biomarkers. These issues are relevant to each of
the other articles in the mini-monograph.
Kosnett et al. (2007) summarize recom-
mendations for management of adults with
lead exposure. This article was prepared by a
majority of members of an expert panel (8 of
13 members) and offers advice to public health
professionals and clinicians in the medical and
nonmedical management of lead-exposed
adults. The expert panel’s ﬁnal document also
went to the AOEC for additional editing,
which resulted in the greatly shortened manu-
script on the AOEC website AOEC 2006).
Adult lead exposure
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AOEC website were not written by panel
members; rather, they were rewritten by a
small committee of AOEC members.
Navas-Acien et al. (2007) review the epi-
demiologic evidence evaluating lead exposure
and cardiovascular outcomes. Cardiovascular
outcomes were critical to the deliberations of
the panel, but such detailed analysis of studies
could not be incorporated into the panel’s
main article. Here, the authors consider this
evidence in detail. They summarize the review
articles on blood pressure and hypertension,
but go into great detail on cardiovascular out-
comes other than blood pressure and hyper-
tension, including important clinical ones
(e.g., myocardial infarction).
The review by Shih et al. (2007) is a dis-
cussion of the epidemiologic evidence evaluat-
ing lead exposure and cognitive outcomes.
Like cardiovascular outcomes, many panel
members considered cognitive outcomes to be
from a critical target organ and prevention of
these outcomes was an important motivation.
Here, the authors considered only articles that
measured blood lead, bone lead, and cogni-
tive outcomes, so the key issues discussed by
Hu et al. (2007) could be evaluated.
Other outcomes were also considered by
the panel but additional manuscripts were not
solicited for the mini-monograph for several
reasons. First, at the time of preparation of the
mini-monograph, the U.S. Environmental
Protection Agency (U.S. EPA) was in the
process of updating its Air Criteria Document
for Lead (U.S. EPA 2005) and systematic
reviews of evidence by organ system will be a
result. We are aware of several authors of
chapters for that document who have already
made plans to submit their chapters for publi-
cation in other specialty journals (Ekong et al.
2006). Finally, the CDC has convened a
national panel on lead and reproductive out-
comes (CDC 2006), so we did not solicit a
reproductive chapter in advance of that effort.
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